Asha Pillai

Sep 1, 2023 | science.org | Jonna Alanko |Xin Lan |Hannah Donnelly |Asha Pillai

Editors' ChoiceFOCIS HIGHLIGHTS Immunotherapy harnessing tumor-infiltrating lymphocytes (TILs) is advancing cures for patients with otherwise-intractable solid tumors. Antibody-targeted endogenous CD8+ T cells and ex vivo engineered autologous chimeric antigen receptor T (CAR-T) or tumor specific antigen (TSA)–specific CD8+ T cells (TCR-T) are potent immunotherapies. However, immune escape when tumors downregulate class I or TSA expression is a key challenge to durable responses.

Sep 1, 2023 | sciencemag.org | Jonna Alanko |Xin Lan |Hannah Donnelly |Asha Pillai

Editors' ChoiceFOCIS HIGHLIGHTSImmunotherapy harnessing tumor-infiltrating lymphocytes (TILs) is advancing cures for patients with otherwise-intractable solid tumors. Antibody-targeted endogenous CD8+ T cells and ex vivo engineered autologous chimeric antigen receptor T (CAR-T) or tumor specific antigen (TSA)–specific CD8+ T cells (TCR-T) are potent immunotherapies. However, immune escape when tumors downregulate class I or TSA expression is a key challenge to durable responses.

Feb 10, 2023 | blogs.sap.com | Asha Pillai

In our constant endeavor to give you the best industry practices with of SAP S/4HANA Cloud, Public Edition, we bring to you numerous improvements and innovations with each release . This means that the number of changes with every releases often runs into thousands . With so much on the plate, it often becomes challenging to consume all the changes brought in by a bi-annual release.